PortfoliosLab logoPortfoliosLab logo
REGN vs. NOW
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

REGN vs. NOW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Regeneron Pharmaceuticals, Inc. (REGN) and ServiceNow, Inc (NOW). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, REGN achieves a -20.48% return, which is significantly higher than NOW's -33.32% return. Over the past 10 years, REGN has underperformed NOW with an annualized return of 5.35%, while NOW has yielded a comparatively higher 21.48% annualized return.


REGN

1D
0.11%
1M
-14.00%
YTD
-20.48%
6M
-17.20%
1Y
16.30%
3Y*
-7.00%
5Y*
3.27%
10Y*
5.35%

NOW

1D
-0.90%
1M
12.87%
YTD
-33.32%
6M
-40.96%
1Y
-48.34%
3Y*
-2.72%
5Y*
0.51%
10Y*
21.48%
*Multi-year figures are annualized to reflect compound growth (CAGR)

REGN vs. NOW - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
REGN
Regeneron Pharmaceuticals, Inc.
-20.48%8.96%-18.90%21.73%14.25%30.72%28.66%0.53%-0.65%2.42%
NOW
ServiceNow, Inc
-33.32%-27.75%50.05%81.96%-40.18%17.93%94.97%58.56%36.55%75.40%

Correlation

The correlation between REGN and NOW is -0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.10

Correlation (3Y)
Calculated over the trailing 3-year period

0.05

Correlation (5Y)
Calculated over the trailing 5-year period

0.16

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Jun 29, 2012

0.27

The correlation between REGN and NOW shifts across timeframes, from -0.10 (1 year) to 0.27 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

REGN:

$65.93B

NOW:

$106.24B

EPS

REGN:

$41.05

NOW:

$1.68

PE Ratio

REGN:

14.91

NOW:

60.81

PS Ratio

REGN:

4.42

NOW:

7.65

PB Ratio

REGN:

2.10

NOW:

7.83

Total Revenue (TTM)

REGN:

$14.92B

NOW:

$13.96B

Gross Profit (TTM)

REGN:

$12.61B

NOW:

$10.69B

EBITDA (TTM)

REGN:

$5.74B

NOW:

$2.80B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

REGN vs. NOW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REGN
REGN Risk / Return Rank: 5959
Overall Rank
REGN Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
REGN Sortino Ratio Rank: 5656
Sortino Ratio Rank
REGN Omega Ratio Rank: 5555
Omega Ratio Rank
REGN Calmar Ratio Rank: 5959
Calmar Ratio Rank
REGN Martin Ratio Rank: 6363
Martin Ratio Rank

NOW
NOW Risk / Return Rank: 88
Overall Rank
NOW Sharpe Ratio Rank: 55
Sharpe Ratio Rank
NOW Sortino Ratio Rank: 77
Sortino Ratio Rank
NOW Omega Ratio Rank: 77
Omega Ratio Rank
NOW Calmar Ratio Rank: 1111
Calmar Ratio Rank
NOW Martin Ratio Rank: 88
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

REGN vs. NOW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and ServiceNow, Inc (NOW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


REGNNOWDifference
Sharpe ratioReturn per unit of total volatility

+1.54

Sortino ratioReturn per unit of downside risk

+2.44

Omega ratioGain probability vs. loss probability

1.12

0.82

+0.31

Calmar ratioReturn relative to maximum drawdown

0.70

-0.82

+1.52

Martin ratioReturn relative to average drawdown

2.16

-1.45

+3.61

REGN vs. NOW - Sharpe Ratio Comparison

The current REGN Sharpe Ratio is 0.55, which is higher than the NOW Sharpe Ratio of -0.99. The chart below compares the historical Sharpe Ratios of REGN and NOW, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

REGN vs. NOW - Drawdown Comparison

The maximum REGN drawdown since its inception was -91.81%, which is greater than NOW's maximum drawdown of -64.54%. Use the drawdown chart below to compare losses from any high point for REGN and NOW.


Loading charts...

Drawdown Indicators


REGNNOWDifference

Max Drawdown

Largest peak-to-trough decline

-91.81%

-64.54%

-27.27%

Max Drawdown (1Y)

Largest decline over 1 year

-25.85%

-60.28%

+34.43%

Max Drawdown (3Y)

Largest decline over 3 years

-59.69%

-64.54%

+4.85%

Max Drawdown (5Y)

Largest decline over 5 years

-59.69%

-64.54%

+4.85%

Max Drawdown (10Y)

Largest decline over 10 years

-59.69%

-64.54%

+4.85%

Current Drawdown

Current decline from peak

-48.64%

-56.36%

+7.72%

Average Drawdown

Average peak-to-trough decline

-42.45%

-13.78%

-28.67%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.33%

34.02%

-25.69%

Volatility

REGN vs. NOW - Volatility Comparison

The current volatility for Regeneron Pharmaceuticals, Inc. (REGN) is 12.77%, while ServiceNow, Inc (NOW) has a volatility of 25.56%. This indicates that REGN experiences smaller price fluctuations and is considered to be less risky than NOW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


REGNNOWDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.77%

25.56%

-12.79%

Volatility (6M)

Calculated over the trailing 6-month period

22.14%

47.01%

-24.87%

Volatility (1Y)

Calculated over the trailing 1-year period

32.77%

50.12%

-17.35%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

30.79%

43.44%

-12.65%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

32.17%

40.86%

-8.69%

Dividends

REGN vs. NOW - Dividend Comparison

REGN's dividend yield for the trailing twelve months is around 0.59%, while NOW has not paid dividends to shareholders.


PositionTTM2025
NOW
ServiceNow, Inc
0.00%0.00%
REGN
Regeneron Pharmaceuticals, Inc.
0.59%0.46%

Financials

REGN vs. NOW - Financials Comparison

This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and ServiceNow, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


1.00B2.00B3.00B4.00B5.00B20222023202420252026
3.61B
3.77B
(REGN) Total Revenue
(NOW) Total Revenue
Values in USD except per share items

REGN vs. NOW - Profitability Comparison

The chart below illustrates the profitability comparison between Regeneron Pharmaceuticals, Inc. and ServiceNow, Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

76.0%78.0%80.0%82.0%84.0%86.0%20222023202420252026
81.4%
75.1%
Portfolio components
REGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.

NOW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ServiceNow, Inc reported a gross profit of 2.83B and revenue of 3.77B. Therefore, the gross margin over that period was 75.1%.

REGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.

NOW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ServiceNow, Inc reported an operating income of 503.00M and revenue of 3.77B, resulting in an operating margin of 13.3%.

REGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.

NOW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ServiceNow, Inc reported a net income of 469.00M and revenue of 3.77B, resulting in a net margin of 12.4%.


Frequently Asked Questions


REGN and NOW have a correlation of -0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NOW has higher volatility (25.56%) compared to REGN (12.77%). In terms of maximum drawdown, REGN dropped -91.81% vs NOW's -64.54%.

REGN currently has the higher Sharpe Ratio (0.55 vs -0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for REGN and NOW

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer